The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib.
Read More
Study: Immune Cell That Drives Breast Cancer Could Be Effective Target in Novel Immunotherapies
April 23rd 2021New research findings published in Cell Reports identified a type of immune cells that acts as a major driver of breast cancer growth by preventing the accumulation of a specific protein that induces anti-tumor responses.
Read More
ASHP, APhA Express Support for New Bill Expanding Medicare Patients’ Access to Pharmacists
April 22nd 2021The legislation does not expand scope of practice, but instead brings Medicare rules in alignment with existing responsibilities already granted to pharmacists through various credentialing and privileging programs.
Read More
New Research Provides Insight into COVID-19 Vaccine Reluctancy Among Social Media Users
April 22nd 2021The researchers’ analysis was based on a large representative sample survey carried out in November to December 2020, which examined a range of factors that previous studies had found to be related to hesitancy about getting vaccinated against COVID-19.
Read More
PQA Annual Meeting Will Address Equity, Quality and Value in Medication Use
April 22nd 2021Open to all health care professionals, the PQA meeting is a top forum for learning best practices and emerging trends in medication services, pharmacist-provided care, and quality improvement initiatives.
Read More